Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants

Background. Antibody responses to pneumococcal conjugate vaccines may vary when administered in different populations or epidemiologic settings. Understanding the causes and significance of this variation could help to determine the number of doses and timing required for protection against pneumococcal diseases in each country. Methods. This report compares antibody responses to aluminum-adjuvanted and nonadjuvanted mixed carrier 11-valent diphtheria- or tetanus-conjugated pneumococcal vaccine (11-PncTD) formulations when given at 6, 10 and 14 weeks and 9 months of age to Filipino infants (n = 51) and at 2, 4, 6 and 12 months of age to Finnish (n = 127) and Israeli (n = 124) infants. The study populations differ in their natural exposure to pneumococcus and risk factors for pneumococcal carriage and disease. Results. Filipino and Israeli infants had slightly but significantly higher prevaccination geometric mean concentration (GMC) of antibodies than did the Finnish infants. After three doses of aluminum-adjuvanted 11-PncTD vaccine, the Filipino infants had 1.8 to 6.7 and 1.5 to 5.0 times higher GMC than the Finnish and Israeli infants, respectively, against pneumococcal serotypes conjugated to tetanus protein. The GMC of serotypes conjugated to diphtheria toxoid was 1.3 to 3.0 and 0.7 to 2.0 times the GMC in Finnish and Israeli infants, respectively. The nonadjuvanted vaccine formulation induced generally lower GMCs. Conclusions. The antibody responses to the tetanus-conjugated polysaccharides were considerably higher in the Filipino than in the Finnish or Israeli infants. This may be a result of several factors including the priming effect of tetanus toxoid given to pregnant women, early pneumococcal nasopharyngeal acquisition and genetic differences among populations.

[1]  M. Lucero,et al.  Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants , 2002, The Pediatric infectious disease journal.

[2]  S. Yeh,et al.  Strategies for development of combination vaccines , 2001, The Pediatric infectious disease journal.

[3]  A. Takala,et al.  Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. , 2001, The Journal of infectious diseases.

[4]  G. Overturf.  Technical Report: Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate and Polysaccharide Vaccines and Antibiotic Prophylaxis , 2000, Pediatrics.

[5]  D. Greenberg,et al.  Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Käyhty,et al.  Are the Enzyme Immunoassays for Antibodies to Pneumococcal Capsular Polysaccharides Serotype Specific? , 2000, Clinical Diagnostic Laboratory Immunology.

[7]  S. Obaro.  Prospects for pneumococcal vaccination in African children. , 2000, Acta tropica.

[8]  E. Lewis,et al.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children , 2000, The Pediatric infectious disease journal.

[9]  R. Huebner,et al.  Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. , 1999, The Journal of infectious diseases.

[10]  S. Black,et al.  Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. , 1999, The Pediatric infectious disease journal.

[11]  K. Mulholland.  Strategies for the control of pneumococcal diseases. , 1999, Vaccine.

[12]  J. Eskola,et al.  Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. , 1999, Vaccine.

[13]  M. Roelants,et al.  Priming effect, immunogenicity and safety of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered to infants in Belgium and Turkey. , 1999, Vaccine.

[14]  P. Heath,et al.  Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. , 1998, The Pediatric infectious disease journal.

[15]  M. Levine,et al.  Safety and immunogenicity of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. , 1998, Vaccine.

[16]  P. Ruutu,et al.  Antibody responses of three Haemophilus influenzae type b conjugate vaccines after one, two and three doses in Filipino children. , 1998, Vaccine.

[17]  C. Leclerc,et al.  Reduced Response to Multiple Vaccines Sharing Common Protein Epitopes That Are Administered Simultaneously to Infants , 1998, Infection and Immunity.

[18]  J. Eskola,et al.  Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. , 1998, The Pediatric infectious disease journal.

[19]  S. Obaro,et al.  A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. , 1997, The Pediatric infectious disease journal.

[20]  R. Dagan,et al.  Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. , 1997, The Pediatric infectious disease journal.

[21]  M. Levine,et al.  Factors associated with superior antibody responses to a single dose of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine administered to Chilean infants at 2 months of age. , 1997, Vaccine.

[22]  R. Dagan,et al.  Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: relation to serotypes likely to be included in pneumococcal conjugate vaccines. , 1996, The Journal of infectious diseases.

[23]  S. Kurikka.  Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. , 1996, Vaccine.

[24]  P. Mäkelä,et al.  Comparison of five different vaccination schedules with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. , 1996, The Journal of pediatrics.

[25]  J. Eskola,et al.  Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. , 1996, The Pediatric infectious disease journal.

[26]  J. Eskola,et al.  Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. , 1995, The Journal of infectious diseases.

[27]  D. Greenberg,et al.  Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines. , 1995, The Journal of pediatrics.

[28]  R. Belshe,et al.  Effect of carrier protein priming on antibody responses to Haemophilus influenzae type b conjugate vaccines in infants. , 1994, JAMA.

[29]  K. Edwards,et al.  Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. , 1994, The Pediatric infectious disease journal.

[30]  D. Greenberg,et al.  Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. , 1994, The Journal of infectious diseases.

[31]  D. Granoff,et al.  G2m(23) immunoglobulin allotype and immunity to Haemophilus influenzae type b. , 1992, The Journal of infectious diseases.

[32]  P. Mäkelä,et al.  A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. , 1990, The New England journal of medicine.

[33]  W. Heyward,et al.  Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. , 1990, The New England journal of medicine.

[34]  P. Byass,et al.  Serologic responses to an Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine in very young Gambian infants. , 1990, Pediatrics.

[35]  P. Ruutu,et al.  Effect of transplacentally acquired tetanus antibodies on the antibody responses to Haemophilus influenzae type b-tetanus toxoid conjugate and tetanus toxoid vaccines in Filipino infants. , 1999, The Pediatric infectious disease journal.

[36]  B. Greenwood,et al.  Evaluation of vaccines for the prevention of pneumonia in children in developing countries. , 1999, Epidemiologic reviews.

[37]  A. Hinman,et al.  Haemophilus influenzae type B conjugate vaccine , 1988 .

[38]  G. Koki,et al.  Colonisation of Haemophilus influenzae and Streptococcus pneumoniae in the upper respiratory tract of neonates in Papua New Guinea: primary acquisition, duration of carriage, and relationship to carriage in mothers. , 1986, Biology of the neonate.